Platelet Rich Plasma in Treatment of Melasma

Status Recruiting

Clinical Trial Summary

Melasma is a common acquired disorder characterized by symmetric, hyperpigmented patches with an irregular outline, occurring most commonly on the face. The therapy for melasma has always been challenging and discouraging. Platelet rich plasma has been used over the last several years as an effective treatment in various surgical and medical ﬁelds. In recent years, Platelet rich plasma has also started to be used in the field of cosmetology. This study is designed to evaluate the therapeutic effect of platelet rich plasma in melasma.

Clinical Trial Description

Melasma is a pigmentary disorder that can be disfiguring and can cause to significant emotional stresses for sufferers, for which a universally effective treatment is still lacking. Platelet rich plasma is commonly used in dermatology and plastic surgery, especially for treating chronic wounds, ulcers, and burns. The most important contents of platelets are contained in the α-granules. Some of the bioactive substances present in the α-granules include platelet-derived growth factor, transforming growth factor -β1 and -β2epidermal growth factor, and mitogenic growth factors such as platelet-derived angiogenesis factor and fibrinogen.

transforming growth factor -β1 decreases melanogenesis via delayed extracellular signal-regulated kinase activation. The regression of melasma in a 27-years-old woman after injecting platelet rich plasma for skin rejuvenation was observed, but controlled clinical trials are still lacking to confirm this preliminary observation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03308370
Study type	Interventional
Source	Assiut University
Contact	Eman R Hofny, PHD
Phone	01005298992
Email	e_riad@yahoo.com
Status	Recruiting
Phase	Phase 3
Start date	November 1, 2017
Completion date	December 7, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05013801` - A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma	N/A
Recruiting	`NCT06174545` - Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma	N/A
Completed	`NCT01695356` - Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma	Phase 4
Recruiting	`NCT06278948` - Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma	N/A
Not yet recruiting	`NCT05911698` - Fractional co2 Laser Followed by Either Vitamin c or Tranexamic Acid in Treatment of Melasma.	N/A
Recruiting	`NCT05656833` - Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma	N/A
Recruiting	`NCT04597203` - Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial	N/A
Completed	`NCT02138539` - Evaluation of an Herbal-Based De-Pigmenting System	Phase 4
Recruiting	`NCT01661556` - Clinical Trial of Hydroquinone Versus Miconazol in Melasma	Phase 4
Completed	`NCT01001624` - Melanil in the Treatment of Melasma	Phase 3
Terminated	`NCT03415685` - Lutronic PicoPlus Exploratory Clinical Trial	N/A
Recruiting	`NCT04765930` - Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma	N/A
Completed	`NCT04137263` - Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging	N/A
Recruiting	`NCT03686787` - Oral Tranexamic Acid and Laser for Treatment of Melasma	Phase 4
Completed	`NCT05969587` - Cysteamine Compared to Hydroquinone in Melasma	Phase 3
Completed	`NCT00500162` - Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma	Phase 4
Completed	`NCT00472966` - Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma	Phase 4
Completed	`NCT05887219` - Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma	Phase 1
Completed	`NCT05884151` - Comparison of Intralesional Tranexamic Acid and Platelets Rich Plasma in the Treatment of Melasma	Phase 1
Not yet recruiting	`NCT05099601` - Silymarin Cream Versus Combined Silymarin Cream and Microneedling in Treatment of Melasma	Phase 4